Sage Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes medicines to treat central nervous system disorders. The company's lead product candidate is ZULRESSO, which is used for the treatment of postpartum depression. It also develops SAGE-217, a novel neuroactive steroid for the treatment of various CNS disorders, including major depressive disorder, postpartum depression, bipolar depression, and insomnia. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.